Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDMEN trial of intratympanic methylprednisolone for unilateral Menière's disease
NL-OMON59508Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Meniere Disease comparing Intratympanic methylprednisolone with Placebo (2 arms). Primary endpoint: Complete or substantial control of vertigo. Started Oct 2023; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on NL-OMON59508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59508.